Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Guizhou Sinorda Biotechnology Co. Ltd. operates within the Biotechnology & Pharmaceuticals technology area. The company has 1 pending office action currently under review. This prosecution involves 1 distinct examiner and 1 distinct art unit, reflecting a concentrated effort in a specialized field. Such a focus suggests that the company's intellectual property strategy is currently centered on a specific technical niche within the broader Biotechnology & Pharmaceuticals field.
NATARAJAN, MEERA is the busiest examiner for the portfolio, with 1 pending office action. Since the company only has 1 pending office action in total, NATARAJAN, MEERA is responsible for the 1 pending office action currently active. The outcome for this biotechnology portfolio is currently tied to the specific examination patterns of this 1 distinct examiner and the 1 distinct art unit involved. For a practitioner, this implies that understanding the historical allowance rates and preferences of NATARAJAN, MEERA is critical for success.
The presence of only the 1 distinct art unit further reinforces the specialized nature of the company's current filings. With the pending office action as the only active matter, the company's immediate legal focus is streamlined. This lack of diversity in examiners and art units simplifies the management of the portfolio but also increases the impact of any single decision made by the assigned examiner within the Biotechnology & Pharmaceuticals sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NATARAJAN, MEERA | 1 | 62.6% | +17.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18279550 | New Treatment of Sepsis | NATARAJAN, MEERA | — |
| Art Unit | Apps |
|---|---|
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18279550 | New Treatment of Sepsis | NATARAJAN, MEERA | 1643 | §102 | Non-Final OA | — | Pending | Aug 30, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGuizhou Sinorda Biotechnology Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Meera Natarajan has the most, with 1 of Guizhou Sinorda Biotechnology Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
